following an abbreviated submission:
doravirine (Pifeltro®) is accepted for use within NHSScotland.
Indication under review: in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
Doravirine offers an additional treatment choice in the therapeutic class of NNRTIs for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice630KB (PDF)
Medicine details
- Medicine name:
- doravirine (Pifeltro)
- SMC ID:
- SMC2332
- Indication:
In combination with other antiretroviral medicinal products, for the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 March 2021